Commercial License Agreement Sample Contracts
EX-10.14 3 filename3.htmCommercial License Agreement • May 5th, 2020
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
Standard Contracts
SELEXIS COMMERCIAL LICENSE AGREEMENT ENTERED INTO WITH BIOGENERICS, INC.Commercial License Agreement • September 25th, 2014 • Coherus BioSciences, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Commercial License Agreement (the “Agreement”) is made effective on April 8, 2011 (the “Effective Date”), by and between SELEXIS SA, 18 chemin des Aulx, 1228 Plan-les-Ouates, Geneva, Switzerland SA (“Selexis”) and BIOGENERICS, INC. 555 Bryant Street, Ste 266, Palo Alto, CA 94301 (“COMPANY”).
Commercial License AgreementCommercial License Agreement • October 9th, 2020 • Opthea LTD • Biological products, (no disgnostic substances)
Commercial License Agreement for the CALLHOME Lexicon DatabasesCommercial License Agreement • October 15th, 2020 • Pennsylvania
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • June 19th, 2020 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Commercial License Agreement (“Agreement”) is entered into effective April 27, 2017 (“Effective Date”) by TeneoBio, Inc. (“TeneoBio”), having its principal place of business at 1490 O’Brien Drive, Suite D, Menlo Park, CA 94025, and Poseida Therapeutics, Inc. (“Licensee”), having its principal place of business at 4242 Campus Point Court, #700, San Diego, CA 92121. In consideration of the mutual covenants and promises set forth in this Agreement, the parties agree as follows:
CONFIDENTIAL TREATMENT REQUESTED. CERTAIN PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION.]Commercial License Agreement • July 12th, 2004 • Xenogen Corp • Services-commercial physical & biological research • California
This Agreement (the “Agreement”) effective as of July 12, 2000 (the “Effective Date”) is made by and between Xenogen Corporation, having a principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and IRM, LLC, a Delaware Corporation, (“IRM”), having a principal place of business at Sofia House, 48 Church Street, Hamilton, Bermuda.
Addendum to Commercial AgreementsCommercial License Agreement • January 25th, 2022
The Contractor acknowledges and agrees this Addendum will become a binding part of any contract with the U.S. Senate, Office of the Sergeant at Arms (SAA) in the event Contractor’s proposal is accepted and selected for award and shall be an attachment to the Commercial License Agreement, whether called an End User License Agreement, Terms of Service, Maintenance Agreement, or another similar legal instrument or agreement (collectively referred to as “License Agreement”).
ONLYOFFICE Integration Edition LICENSE AGREEMENTCommercial License Agreement • November 10th, 2021
IMPORTANT ‑ READ CAREFULLY: BY INSTALLING, DOWNLOADING OR OTHERWISE USING ONLYOFFICE AND ANY RELATED DOCUMENTATION, YOU, ON BEHALF OF YOURSELF OR AS AN AUTHORIZED REPRESENTATIVE ON BEHALF OF AN ENTITY (“LICENSEE”) AGREE TO ALL THE TERMS OF THIS ONLYOFFICE COMMERCIAL LICENSE AGREEMENT (THE “AGREEMENT”) REGARDING YOUR USE OF ONLYOFFICE INTEGRATION EDITION. YOU REPRESENT AND WARRANT THAT YOU HAVE FULL LEGAL AUTHORITY TO BIND THE LICENSEE TO THIS AGREEMENT. IF YOU DO NOT AGREE WITH ALL OF THESE TERMS, DO NOT INSTALL, DOWNLOAD OR OTHERWISE USE ONLYOFFICE.
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • April 10th, 2013 • BioAmber Inc. • Industrial organic chemicals
This Commercial License Agreement (“Commercial License”), effective the 15th day of April, 2010 (“Effective Date”), is made by and between Cargill, Inc., through its Bio Technology Development Center, having its principal place of business at 15407 McGinty Road West, Wayzata, MN 55391 (hereinafter “Cargill”), and Bioamber S.A.S., having a place of business at Route de Bazancourt, F-51110, Pomacle France (“Bioamber”). Cargill and Bioamber are referred to herein as “Parties”, in singular or plural usage, as required by context.
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • June 19th, 2020 • Poseida Therapeutics, Inc. • Biological products, (no disgnostic substances) • California
This Commercial License Agreement (“Agreement”) is entered into effective August 3, 2018 (“Effective Date”) by TeneoBio, Inc. (“TeneoBio”), having its principal place of business at 1490 O’Brien Drive, Suite D, Menlo Park, CA 94025, and Poseida Therapeutics, Inc. (“Licensee”), having its principal place of business at 4242 Campus Point Court, #700, San Diego, CA 92121. In consideration of the mutual covenants and promises set forth in this Agreement, the parties agree as follows:
EX-10.28 7 dex1028.htm COMMERCIAL LICENSE AGREEMENT DATED AS OF FEBRUARY 18, 2010 COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • May 5th, 2020 • Washington
THIS LICENSE AGREEMENT (hereinafter “License” or “Agreement”) is by and between Med-Fit Systems, Inc. a California corporation (“Buyer”) and Nautilus, Inc., a Washington corporation (“Nautilus”) (collectively the “Parties”). This License is an exhibit to an Asset Purchase Agreement (the “APA”) entered into on the same date between the Parties.
EX-10.33 4 d244198dex1033.htm COMMERCIAL LICENSE AGREEMENT *** Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) and 203.406 COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • May 5th, 2020
This Commercial License Agreement (“Commercial License”), effective the 15th day of April, 2010 (“Effective Date”), is made by and between Cargill, Inc., through its [***], having its principal place of business at [***] (hereinafter “Cargill”), and Bioamber S.A.S., having a place of business at Route de Bazancourt, F-51110, Pomacle France (“Bioamber”). Cargill and Bioamber are referred to herein as “Parties”, in singular or plural usage, as required by context.
Text Omitted and Filed Separately with the Securities and Exchange Commission Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 230.406 COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • July 8th, 2014 • Sage Therapeutics, Inc. • Pharmaceutical preparations • California
avoidance of doubt, if the same Licensed Product first achieves one or more given milestones for two Additional Subfields, then the milestone payment for that event must be paid twice; and in no event shall the maximum payment under this Section 4.1(b)(ii) exceed $[…***…]) are as follows. Subject to the preceding sentence, if any such milestone is achieved in the relevant Additional Subfield before all prior sequential milestones have been actually achieved in such Additional Subfield, then any and all prior sequential milestones which were not previously actually achieved with respect to such Additional Subfield shall be deemed to have thereby been achieved, and the milestone payments for such deemed-achieved milestones shall also be payable with respect to such Additional Subfield within such […***…] days.
AMENDMENT 1 TO THE COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • July 3rd, 2017 • Calyxt, Inc. • Agricultural chemicals
This AMENDMENT 1 TO THE COMMERCIAL LICENSE AGREEMENT (this “Amendment”) is made effective as of December 1, 2016 (the “Amendment Effective Date”) by and between CALYXT, INC. (previously known as CELLECTIS PLANT SCIENCES, INC., with the change of name occurring on or about May 5, 2015), a company existing and registered under the laws of Delaware, located at 600 County Road D West, Suite 8, New Brighton, MN 55112, USA, under the EIN number 27-1967997, represented by Federico Tripodi acting as Chief Executive Officer (CEO) duly authorized for the purposes hereof (“CALYXT” or “CPS”) and Two Blades Foundation, a not-for-profit corporation organized and existing under the laws of the State of Delaware with its principal place of business at 1630 Chicago Avenue, Suite 1907, Evanston, IL 60201, USA (“2 Blades”; CPS and 2 Blades, each a “Party” and collectively, the “Parties”).
BACKGROUNDCommercial License Agreement • January 26th, 2001 • Xenogen Corp • Services-commercial physical & biological research • California
Commercial License Agreement for Lassalle Technologies AddFlow ScriptCommercial License Agreement • November 23rd, 2023
THIS COMMERCIAL LICENSE AGREEMENT IS A BINDING AGREEMENT BETWEEN YOU AND PATRICK LASSALLE. IT CONTAINS THE TERMS AND CONDITIONS FOR YOUR USE OF “ADDFLOW SCRIPT”. BY USING THIS SOFTWARE, YOU ARE AGREEING TO BE BOUND BY THE FOLLOWING TERMS AND CONDITIONS:
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO ELEVATION ONCOLOGY, INC. IF PUBLICLY DISCLOSED. COMMERCIAL LICENSE AGREEMENT ENTERED...Commercial License Agreement • May 14th, 2021 • Elevation Oncology, Inc. • Biological products, (no disgnostic substances)
Whereas, Merrimack is a biopharmaceutical company engaged in the research, development, manufacturing and sale of biopharmaceutical products; and
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • July 3rd, 2017 • Calyxt, Inc. • Agricultural chemicals • New York
THIS COMMERCIAL LICENSE AGREEMENT (this “Agreement”) is made and entered into as of December 9, 2014 (the “Effective Date”), by and between Cellectis Plant Sciences, Inc. a corporation organized and existing under the laws of the State of Delaware with its principal place of business at 8, rue de la Croix Jarry, 75013 Paris, France (“CPS”), and Two Blades Foundation, a not-for-profit corporation organized and existing under the laws of the State of Delaware with its principal place of business at 1630 Chicago Avenue, Suite 1907, Evanston, IL 60201, USA (“2 Blades”; CPS and 2 Blades, each a “Party” and collectively, the “Parties”).
GE Digital Commercial Off the Shelf License Terms and Conditions (06/2016)Commercial License Agreement • August 26th, 2016 • New York
This Agreement (also referred to as “Order”) is made by Licensor, a company whose address and primary contact information are contained on the face of the GE purchase order (“Order Document”) to which these terms apply, and General Electric Company, a company organized and existing under the laws of the State of New York, U.S.A., and acting through GE Digital LLC with a place of business at 2623 Camino Ramon, San Ramon, CA 94583, U.S.A. (“GE”).
Squish Commercial License AgreementCommercial License Agreement • January 28th, 2021 • Hamburg
This froglogic Squish Commercial License Agreement ("Agreement") is made by and between froglogic GmbH ("froglogic"), and you (either an individual or a legal entity) ("Licensee").
ONLYOFFICE Enterprise Edition LICENSE AGREEMENTCommercial License Agreement • May 16th, 2020
IMPORTANT - READ CAREFULLY: BY INSTALLING, DOWNLOADING OR OTHERWISE USING ONLYOFFICE AND ANY RELATED DOCUMENTATION, YOU, ON BEHALF OF YOURSELF OR AS AN AUTHORIZED REPRESENTATIVE ON BEHALF OF AN ENTITY (“LICENSEE”) AGREE TO ALL THE TERMS OF THIS ONLYOFFICE COMMERCIAL LICENSE AGREEMENT (THE “AGREEMENT”) REGARDING YOUR USE OF ONLYOFFICE ENTERPRISE EDITION. YOU REPRESENT AND WARRANT THAT YOU HAVE FULL LEGAL AUTHORITY TO BIND THE LICENSEE TO THIS AGREEMENT. IF YOU DO NOT AGREE WITH ALL OF THESE TERMS, DO NOT INSTALL, DOWNLOAD OR OTHERWISE USE ONLYOFFICE.
Pfēnex Expression Technology™ COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • January 23rd, 2006 • Iomai Corp • Pharmaceutical preparations • Delaware
This Agreement is effective as of the latest date of signing below and is by and between Dow Global Technologies Incorporated (“Dow”), a Michigan corporation having its principal offices at 2030 Dow Center, Midland, MI, 48674 USA and Iomai Corporation, a Delaware corporation (“Licensee”) having a principal place of business at 20 Firstfield Road Suite 250, Gaithersburg, MD 20878 USA
COMMERCIAL LICENCE AGREEMENTCommercial License Agreement • January 28th, 2014 • Dicerna Pharmaceuticals Inc • Pharmaceutical preparations • New York
PLANT BIOSCIENCE LIMITED, a company registered in England whose registered office is at Norwich Research Park, Colney Lane, Norwich NR4 7UH, England (hereinafter “PBL”) and
Pfenex Expression Technology™ COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • April 2nd, 2009 • Inovio Biomedical Corp • Surgical & medical instruments & apparatus • Delaware
This Agreement is effective as of the latest date of signing below and is by and between Dow Global Technologies Incorporated ("Dow"), a Delaware corporation having its principal offices at 2030 Dow Center, Midland, MI, 48674 USA and VGX Pharmaceuticals, Inc, a Delaware corporation ("VGX") having a principal place of business at 450 Sentry Parkway, Blue Bell, PA 19422.
EGENIX.COM COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • September 13th, 2021
EX-10.22 6 f10k2014ex10xxii_enercore.htm COMMERCIAL LICENSE AGREEMENT-EXECUTED REDACTED CONFIDENTIAL TREATMENT REQUESTED COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • May 5th, 2020 • New York
This COMMERCIAL LICENSE AGREEMENT (“Agreement”) is made as of the 14th day of November, 2014, (“Effective Date”) by and between Dresser-Rand Company, a New York general partnership (“D-R”), and Ener-Core Power, Inc., a Delaware corporation (“E-C”) (each a “Party” and, together, the “Parties”).
MixItUp Commercial License Agreement v2.1Commercial License Agreement • December 8th, 2021
This Commercial License Agreement is a binding legal agreement between you and KunkaLabs Limited (KunkaLabs). By installing, copying, or using MixItUp and/or its extensions (the Software), you agree to be bound by the terms of this Agreement.
Agreement will lead to grid-friendly electric vehicle chargingCommercial License Agreement • October 17th, 2021
IMPORTANT. Read the following NXP MQX RTOS Software Commercial License Agreement (“Agreement”) completely. By selecting the “I Accept” button at the end of this page, you indicate that you accept the terms of the Agreement and you acknowledge that you...Commercial License Agreement • April 9th, 2019 • Texas
This Agreement, effective as of the date of the purchase and completed download of the Licensed Software (“Effective Date”), is entered into between you, as an authorized representative of your employer, or if you have no employer, as an individual (together “you” or “Licensee”), and NXP USA Inc. (“NXP”). It concerns your rights to use the MQX RTOS software purchased under the License Type identified during the Order Process and provided to you in binary or source code form and any accompanying written materials (the “Licensed Software”). The Licensed Software may include any updates or error corrections or documentation relating to the Licensed Software provided to you by NXP under this Agreement. In consideration for NXP providing you access to download the Licensed Software, you agree to be bound by the terms of this Agreement. If you do not agree to all of the terms of this Agreement, do not download or install the Licensed Software.
Unlock file and Commercial License AgreementCommercial License Agreement • August 9th, 2018
Each purchase will include an unlock file(s), which will lift the restrictions of the associated application. These restrictions have become active after the Grace Day period has expired, and said restrictions are thus lifted with the presence of the correct, valid unlock file. Re-installing the application will not affect the Grace Day period. The Commercial License Agreement is an additional document that is sent to the customer, but only when being part of the purchase.
Crunchfish signs agreement with Lenovo for XR Skeleton StereoCommercial License Agreement • May 31st, 2022
Crunchfish Gesture Interaction AB ("Crunchfish") signs a commercial license agreement with Lenovo, to provide Lenovo’s new AR-glasses with Crunchfish’s latest hand tracking technology - XR Skeleton Stereo. Lenovo has integrated the software in their AR glasses to enable touchless interaction. It is a 2-years agreement, with a business model that includes an upfront fee as well as a running royalty per produced unit that includes Crunchfish’s software.
COMMERCIAL LICENSE AGREEMENT GENERAL TERMS & CONDITIONSCommercial License Agreement • April 19th, 2019 • Wisconsin
These Commercial License Agreement General Terms & Conditions (the “Terms & Conditions”) govern and supplement the license terms described in this License Details form (the “License Details”) entered into between ACLED Analysis, Incorporated, a Wisconsin corporation with offices at 361 Falls Rd. #501 - Grafton, WI 53024 ("Licensor"), and the licensee identified therein (“Licensee”) effective as of the effective date set forth therein (the “Effective Date”). Together, the License Details and these Terms & Conditions constitute the “Agreement.”
ONLYOFFICE Document Builder LICENSE AGREEMENTCommercial License Agreement • August 16th, 2017
YOURSELF OR AS AN AUTHORIZED REPRESENTATIVE ON BEHALF OF AN ENTITY (“LICENSEE”) AGREE TO ALL THE TERMS OF THIS ONLYOFFICE COMMERCIAL LICENSE AGREEMENT (THE “AGREEMENT”) REGARDING YOUR USE OF ONLYOFFICE DOCUMENT BUILDER. YOU REPRESENT AND WARRANT THAT YOU HAVE FULL LEGAL AUTHORITY TO BIND THE LICENSEE TO THIS AGREEMENT. IF YOU DO NOT AGREE WITH ALL OF THESE TERMS, DO NOT CLICK THE “I ACCEPT” BUTTON AND DO NOT INSTALL, DOWNLOAD OR OTHERWISE USE ONLYOFFICE.
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • October 28th, 2020
BETWEEN : Katholieke Universiteit Leuven, for the purposes of this agreement represented by K.U. LEUVEN RESEARCH & DEVELOPMENT, with headquarters in Belgium at 3000 Leuven, Groot Begijnhof 58-59, and represented by Prof. Dr. ir. K. Debackere, Managing Director and Mr. P. Van Dun, Director,
COMMERCIAL LICENSE AGREEMENTCommercial License Agreement • October 18th, 2019 • Virginia
This Enterprise Endpoint Management Platform, Data Collector, Data Management Node and Tactical TYCHON License Agreement (“Agreement”) describes the relationship between TYCHON, LLC (“Company”) and the licensee identified by the act of acquiring through an authorized transaction (“Licensee”) (collectively, the “Parties”) and includes the License Terms and Conditions and all Addenda that are separately executed by the Parties. This Agreement will become effective when this order is made and accepted by the Company or the distributor, reseller or other business partner (“Authorized Partner”) of Company.
